Benjamin Ellezam

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6566715/publications.pdf

Version: 2024-02-01

36	2,449	394421	395702
papers	citations	19	33
		h-index	g-index

38	38	38	4451
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genetics, 2014, 46, 462-466.	21.4	381
2	Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nature Medicine, 2014, 20, 1147-1156.	30.7	380
3	H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis. Nature Communications, 2019, 10, 1262.	12.8	215
4	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications, 2016, 7, 11185.	12.8	197
5	Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. Acta Neuropathologica, 2016, 131, 847-863.	7.7	143
6	Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas. Cancer Cell, 2019, 35, 782-797.e8.	16.8	143
7	Stalled developmental programs at the root of pediatric brain tumors. Nature Genetics, 2019, 51, 1702-1713.	21.4	136
8	Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathologica, 2014, 128, 733-741.	7.7	116
9	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer, 2019, 19, 1250.	2.6	93
10	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell, 2020, 183, 1617-1633.e22.	28.9	93
11	Trametinib for progressive pediatric low-grade gliomas. Journal of Neuro-Oncology, 2018, 140, 435-444.	2.9	75
12	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell, 2019, 36, 51-67.e7.	16.8	69
13	Adult pilocytic astrocytomas: clinical features and molecular analysis. Neuro-Oncology, 2014, 16, 841-847.	1.2	59
14	Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas. Acta Neuropathologica, 2012, 124, 449-451.	7.7	50
15	Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Research and Therapy, 2020, 22, 5.	3.5	48
16	Adult brainstem gliomas: Correlation of clinical and molecular features. Journal of the Neurological Sciences, 2015, 353, 92-97.	0.6	44
17	Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers. JAMA Network Open, 2019, 2, e192906.	5.9	36
18	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients. Current Oncology, 2021, 28, 346-366.	2.2	27

#	Article	IF	Citations
19	Biallelic variants in the transcription factor PAX7 are a new genetic cause of myopathy. Genetics in Medicine, 2019, 21, 2521-2531.	2.4	25
20	Brainstem angiocentric gliomas with MYBâ€“QKI rearrangements. Acta Neuropathologica, 2017, 134, 667-669.	7.7	20
21	Novel Recessive TNNT1 Congenital Coreâ€Rod Myopathy in French Canadians. Annals of Neurology, 2020, 87, 568-583.	5.3	19
22	Histopathological features of systemic sclerosis-associated myopathy: A scoping review. Autoimmunity Reviews, 2021, 20, 102851.	5.8	17
23	Astrocytes in the Pathogenesis of Multiple Sclerosis: An In Situ MicroRNA Study. Journal of Neuropathology and Experimental Neurology, 2019, 78, 1130-1146.	1.7	13
24	Transarterial Onyx Embolization of an Orbital Solitary Fibrous Tumor. Ocular Oncology and Pathology, 2015, 1, 98-102.	1.0	12
25	SYK is a target of lymphocyte-derived microparticles in the induction of apoptosis of human retinoblastoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 1613-1622.	4.9	9
26	Multisystem Proteinopathy Associated with a VCP G156S Mutation in a French Canadian Family. Canadian Journal of Neurological Sciences, 2020, 47, 412-415.	0.5	7
27	Capillary basement membrane reduplication in myositis patients with mild clinical features of systemic sclerosis supports the concept of â€˜scleromyositisâ€™. Acta Neuropathologica, 2021, 142, 395-397.	7.7	7
28	Mucolipidosis type IV in a child. Journal of AAPOS, 2018, 22, 469-471.	0.3	6
29	Statin-associated anti-HMGCR immune-mediated necrotizing myopathy with dermatomyositis-like features: A case report. SAGE Open Medical Case Reports, 2020, 8, 2050313X2098412.	0.3	3
30	CTNI-67. EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN EXPANDED DATASET. Neuro-Oncology, 2020, 22, ii58-ii58.	1.2	2
31	LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. Neuro-Oncology, 2020, 22, iii371-iii371.	1.2	1
32	French-Canadian families from Saguenay-Lac-Saint-Jean: a new founder population for APECED. Endocrine, 2021, , 1.	2.3	1
33	Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report. BMC Rheumatology, 2022, 6, 11.	1.6	1
34	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. Neuro-Oncology, 2020, 22, iii327-iii328.	1.2	0
35	Corneal imaging with optical coherence tomography assisting the diagnosis of mucolipidosis type IV. Canadian Journal of Ophthalmology, 2021, 56, e120-e121.	0.7	0
36	CTNI-24. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. Neuro-Oncology, 2020, 22, ii47-ii47.	1.2	0